Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
65 hedge funds and large institutions have $63.8M invested in Pardes Biosciences, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 12 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
4% less funds holding
Funds holding: 68 → 65 (-3)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
27% less capital invested
Capital invested by funds: $87.2M → $63.8M (-$23.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.58M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$922K |
| 3 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$808K |
| 4 |
Walleye Capital
New York
|
+$338K |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.4M |
| 2 |
Goldman Sachs
New York
|
-$4.62M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$1.56M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.4M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$591K |
PRDS Hedge Fund Activity: Q4 2022 in Review
65 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q4 2022, worth a combined $63.8M — down 27% from $87.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PRDS and 11 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 20 added.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $1.58M. The largest seller was RA Capital Management, exiting entirely with an estimated $11.4M sold.
- 65 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q4 2022, down from 68 in Q3 2022.
- Funds reported $63.8M of Pardes Biosciences, Inc. Common Stock stock for Q4 2022, down 27% quarter-over-quarter.
- 11 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q4 2022 and 12 closed out, a net change of -1 holder.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q4 2022 was Soleus Capital Management, an estimated $1.58M added.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q4 2022 was RA Capital Management, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2022.